Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic de-escalation based on adalimumab TDM in chronic non-infectious uveitis
2023-509733-39-00Phase 4Authorised
- Sponsor
- CHU Saint-Etienne
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, single-arm trial of adalimumab in uveitis, sponsored by CHU Saint-Etienne. Primary endpoint: Primary composite endpoint at week 48. Planned start Feb 2025; status: authorised.
02
Drugs
03
Conditions
uveitis
Beyond the preview
Go deeper on 2023-509733-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509733-39-00.